低频JAK2V617F克隆驱动骨髓增殖性肿瘤病理并重塑造血系统
研究建立可追踪的小鼠骨髓增殖性肿瘤模型,将CD45.2来源的5.0×10^6个JAK2V617F供体细胞移植入未预处理CD45.1受体小鼠。受体出现真性红细胞增多症样表型,外周血供体细胞嵌合率平均2.7%。移植8个月后,供体来源细胞红系和髓系转录本上调、淋系下调,受体来源细胞也向MPN样表型偏移,骨髓基质骨间充质转录本丢失并伴骨小梁丢失。
要点
- 低频JAK2V617F克隆(平均嵌合率2.7%)即可引起真性红细胞增多症样表型。
- 未突变受体造血细胞也出现髓系和红系转录本上调,向MPN样表型偏移。
- JAK2V617F移植受体骨髓基质骨间充质转录本丢失,并出现骨小梁丢失。
核心结论
- 低频MPN驱动细胞在未预处理受体中不仅影响造血支持基质,还深刻影响未突变细胞,独特改变其转录组和表型。
- 这些观察挑战了当前对MPN和其他CHIP相关疾病病因及治疗策略的理解。
研究设计与样本
- 研究建立可追踪的小鼠MPN模型,采用全骨髓移植:将CD45.2来源的5.0×10^6个JAK2V617F供体细胞移植入未预处理CD45.1受体小鼠。
- 移植后8个月,按CD45.1/CD45.2表达分选骨髓细胞进行RNA测序分析,并对骨髓基质进行RNA测序,同时行微计算机断层扫描成像。
主要发现
- 骨髓移植受体出现真性红细胞增多症样表型(红细胞压积升高和白细胞增多),外周血供体细胞嵌合率平均为2.7%。
- 移植8个月后,供体来源细胞中早期红系祖细胞和髓系细胞特异性转录本显著上调,淋系转录本下调(与对照相比)。
- 受体来源细胞也显示髓系和红系祖细胞相关转录本上调,表明非JAK2V617F携带的受体造血系统向MPN样表型偏移。
- JAK2V617F骨髓移植受体的骨髓基质RNA测序显示骨间充质转录本显著丢失,微计算机断层扫描成像一致显示骨小梁丢失。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
JAK2V617F is one of the most common mutations in clonal hematopoiesis of indeterminate potential (CHIP) and a major driver of myeloproliferative neoplasms (MPNs). To determine the impact of a low-frequency JAK2V617F clone on both the hematopoietic system and the bone marrow (BM) stroma, we developed a traceable murine MPN model, in which whole BM transplantation (BMT) was performed using CD45.2 5.0 × 106 JAK2V617F donor cells transplanted into unconditioned CD45.1 recipient mice. BMT recipients developed a polycythemia vera-like phenotype (elevated hematocrit and leukocytosis) with a 2.7% average donor cell chimerism in peripheral blood. Eight months after BMT, RNA sequencing (RNA-seq) analysis of BM cells sorted according to CD45.1/CD45.2 expression showed significant upregulation of early erythroblast- and myeloid cell-specific transcripts, and downregulation of lymphoid transcripts in donor-derived cells compared to controls. Surprisingly, recipient-derived cells also showed upregulation of myeloid- and erythroblast-related transcripts, indicating a skewing of the non-JAK2V617F-carrying recipient hematopoietic system toward an MPN-like phenotype. In addition, RNA-seq analysis of the BM stroma from JAK2V617F BMT recipients indicated significant loss of osteomesenchymal transcripts. Consistently, micro-computed tomography imaging indicated loss of trabecular bone. In sum, our results indicate that low-frequency MPN-driving cells in unconditioned recipients not only impact hematopoiesis-supporting stroma but also profoundly influence unmutated cells, uniquely altering their transcriptomic and phenotypic profiles. These observations are challenging our current understanding of the etiology and therapeutic approaches to MPNs and other CHIP-associated diseases.
引用
- Bonal DM, Oakes A, Chorzalska A, et al. HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology. Blood. 2025. PMID: 40729727. doi:10.1182/blood.2024027125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。